GV has thrown its weight behind Monte Rosa Therapeutics, which is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.
US-based biotechnology developer Monte Rosa Therapeutics picked up $96m in a series B round on Thursday backed by GV, an early-stage investment subsidiary of internet technology group Alphabet.
Aisling Capital led the round, while Versant Ventures, New Enterprise Associates (NEA), HBM Healthcare Investments, Cormorant Asset Management, Amzak Health, Casdin Capital, Sixty Degree Capital and Cambridge Asset Management also took part.
Monte Rosa Therapeutics is working on precision medicine to degrade proteins causing diseases such as cancer. The company’s approach exploits…
